Consolidated Statements of Income (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010
Revenues:
Product sales	$ 4,406.7		$ 3,950.2		$ 3,128.2
Royalties	241.6		283.5		328.1
Other revenues	32.9		29.7		14.8
Total revenues	4,681.2		4,263.4		3,471.1
Costs and expenses:
Cost of product sales	645.4	[1],[2]	588.1	[1],[3]	463.4	[1],[4]
Research and development	965.5	[1],[2]	770.7	[1],[3]	661.5	[1],[4]
Selling, general and administrative	2,114.0	[1],[2]	1,751.4	[1],[3]	1,526.3	[1],[4]
(Gain)/loss on sale of product rights	(18.1)		6.0		(16.5)
Reorganization costs	0		24.3		34.3
Integration and acquisition costs	25.2		13.7		8.0
Total operating expenses	3,732.0		3,154.2		2,677.0
Operating income	949.2		1,109.2		794.1
Interest income	3.1		1.9		2.4
Interest expense	(38.2)		(39.1)		(35.1)
Other (expense)/ income, net	(2.7)		18.1		7.9
Total other expense, net	(37.8)		(19.1)		(24.8)
Income before income taxes and equity in earnings of equity method investees	911.4		1,090.1		769.3
Income taxes	(167.0)		(227.6)		(182.7)
Equity in earnings of equity method investees, net of taxes	1.0		2.5		1.4
Net income	$ 745.4		$ 865.0		$ 588.0
Earnings per ordinary share - basic	$ 1.342		$ 1.569		$ 1.077
Earnings per ordinary share - diluted	$ 1.309		$ 1.509		$ 1.053
Weighted average number of shares:
Basic	555.4	[5]	551.1	[5]	546.2	[5]
Diluted	593.5		595.4		590.3

[1] Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.7 million for the year to December 31, 2012 (2011: $1.7 million, 2010: $1.7 million). Research and development costs include intangible asset impairment charges of $71.2 million for the year to December 31, 2012 (2011: $16.0 million, 2010: $nil). SG&A costs includes amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $320.8 million including impairment losses of $126.7 million for the year to December 31, 2012 (2011: $165.0 million including impairment losses of $nil, 2010: $176.2 million including impairment losses of $42.7 million).

[2] Depreciation from manufacturing plants ($31.5 million) and amortization of favorable manufacturing contracts ($0.7 million) is included in Cost of product sales; depreciation of research and development assets ($22.5 million) and impairment of IPR&D intangible assets in the SP reporting segment ($71.2 million) is included in Research and development; and all other depreciation, amortization and impairment of ($380.6 million) is included in Selling, general and administrative.

[3] Depreciation from manufacturing plants ($39.8 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($25.2 million) and impairment of IPR&D intangible assets in the SP reporting segment ($16.0 million) is included in Research and development; and all other depreciation, amortization and impairment ($228.1 million) is included in Selling, general and administrative.

[4] Depreciation from manufacturing plants ($38.1 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($19.0 million) is included in Research and development; and all other depreciation and amortization ($238.3 million) is included in Selling, general and administrative.

[5] Excludes shares purchased by the EBT and under the share buy-back program and presented by Shire as treasury stock.